Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R

[1]  Lei Wang,et al.  Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R , 2014, BMC Cancer.

[2]  Y Pawitan,et al.  Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer , 2013, Oncogene.

[3]  R. Bast,et al.  Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer , 2012, PloS one.

[4]  G. Tsujimoto,et al.  Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells , 2012, PloS one.

[5]  F. Slack,et al.  MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy , 2011, Nature Reviews Cancer.

[6]  S. Law,et al.  MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor , 2011, Gut.

[7]  M. Sliwkowski,et al.  Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer , 2011, Breast Cancer Research and Treatment.

[8]  C. Arteaga,et al.  Resistance to HER2-directed antibodies and tyrosine kinase inhibitors , 2011, Cancer biology & therapy.

[9]  Chang Gong,et al.  Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer* , 2011, The Journal of Biological Chemistry.

[10]  S. Law,et al.  Characterization of a candidate tumor suppressor gene uroplakin 1A in esophageal squamous cell carcinoma. , 2010, Cancer research.

[11]  H. Park,et al.  FoxM1 mediates resistance to herceptin and paclitaxel. , 2010, Cancer research.

[12]  Michal Ziv-Ukelson,et al.  Gene bi-targeting by viral and human miRNAs , 2010, BMC Bioinformatics.

[13]  Douglas Hanahan,et al.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy , 2010, Proceedings of the National Academy of Sciences.

[14]  A. Laganà,et al.  Prediction of human targets for viral-encoded microRNAs by thermodynamics and empirical constraints , 2010, Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research.

[15]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[16]  M. Seto,et al.  MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. , 2010, Cancer research.

[17]  M. Sliwkowski,et al.  Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.

[18]  Eran Hornstein,et al.  The Promoter of the pri-miR-375 Gene Directs Expression Selectively to the Endocrine Pancreas , 2009, PloS one.

[19]  C. Hudis,et al.  Therapeutic options for metastatic breast cancer , 2009, Expert opinion on pharmacotherapy.

[20]  Michael Reiss,et al.  MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. , 2009, Cancer cell.

[21]  R. Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128)) , 2008 .

[22]  Carlos L Arteaga,et al.  Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network , 2007, Clinical Cancer Research.

[23]  T. Wood,et al.  Insulin-like Growth Factor Type-I Receptor Internalization and Recycling Mediate the Sustained Phosphorylation of Akt* , 2007, Journal of Biological Chemistry.

[24]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[25]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[26]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[27]  David Grimes,et al.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Angela Greco,et al.  A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. , 2004, Gastroenterology.

[29]  Naoto T. Ueno,et al.  P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.

[30]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[31]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.

[32]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[33]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[34]  L. Norton,et al.  Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis , 1995, Cancer.

[35]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Carlos L. Arteaga,et al.  Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.

[37]  R. Nishimura,et al.  Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival , 2008, Breast cancer.

[38]  G. Hortobagyi,et al.  Overview of resistance to systemic therapy in patients with breast cancer. , 2007, Advances in experimental medicine and biology.